13th Jun 2024 10:28
Physiomics PLC - Abingdon, Oxfordshire-based mathematical modelling and data science for new medicines - Wins new contract from "an existing, large client", worth GBP186,000. According to the agreement, the client will use Physiomics' proprietary Virtual Tumour platform to model its targeted oncology agents in combination with other modalities, in order to help inform dose and scheduling decisions. As a result, Physiomics will be entering the next financial year - ending June 30, 2025 - with committed revenue of over GBP500,000.
Chief Executive Officer Peter Sargent says: "After many months of discussion and negotiation with the client, I'm delighted that we can now start this substantial project. This win reflects the significant experience and expertise the Physiomics team has built up over the years, in particular around more complex modelling of combination therapies."
Current stock price: 1.32 pence
12-month change: down 35%
By Holly Beveridge, Alliance News reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Related Shares:
Physiomics